Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Account Payables (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Change in Account Payables data on record, last reported at -$1.2 million in Q3 2025.

  • For Q3 2025, Change in Account Payables fell 276.21% year-over-year to -$1.2 million; the TTM value through Sep 2025 reached $101000.0, down 78.46%, while the annual FY2024 figure was $1.1 million, 334.37% up from the prior year.
  • Change in Account Payables reached -$1.2 million in Q3 2025 per CRVS's latest filing, down from $1.8 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.8 million in Q2 2025 and bottomed at -$2.3 million in Q4 2022.
  • Average Change in Account Payables over 4 years is $27266.7, with a median of $121000.0 recorded in 2023.
  • The widest YoY moves for Change in Account Payables: up 561.87% in 2025, down 1616.67% in 2025.
  • A 4-year view of Change in Account Payables shows it stood at -$2.3 million in 2022, then soared by 105.38% to $121000.0 in 2023, then surged by 485.95% to $709000.0 in 2024, then plummeted by 264.03% to -$1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were -$1.2 million in Q3 2025, $1.8 million in Q2 2025, and -$1.3 million in Q1 2025.